SolnNuc™
Intelligent Nucleic Acid Drug
Development Platform
SolnNuc™
Intelligent Nucleic Acid Drug Development Platform
Intelligent Design for RNA Therapeutics.
Precision and Specificity from Target to Delivery.
Integrating AI with bioinformatics algorithms, SolnNuc™ enables target identification and intelligent sequence design for small nucleic acid therapeutics including siRNA and ASO. Powered by a physics engine and RNA language foundation models, the platform precisely predicts silencing efficacy and off-target risks, enabling highly specific optimization—drastically compressing the candidate space and significantly enhancing development efficiency.
-
Target Discovery
AI algorithms rapidly screen for potential targets amenable to small nucleic acid intervention, expanding the druggable space. -
Sequence Refinement
RNA language models combined with thermodynamic mechanisms lock in the top 0.1% of high-activity sequences from a vast sequence landscape. -
Off-Target Avoidance
Automatically shields seed-region off-target risks and immunogenicity hotspots, embedding upfront safety design . -
Delivery Assessment
Provides comprehensive delivery solutions including GalNAc and LNP across diverse tissues and organs, such as liver and CNS. -
Dry-Wet Closed Loop
Active learning drives a dry-wet closed loop, reducing blind experimental rounds by over 50%, with daily iterative model updates -
Patent Circumvention
AI-generated de novo sequences effectively circumvent existing patent barriers.
SolnNuc™
Intelligent Nucleic Acid Drug
Development Platform
SolnNuc™
Intelligent Nucleic Acid Drug Development Platform
Intelligent Design for RNA Therapeutics.
Precision and Specificity from Target to Delivery.
Integrating AI with bioinformatics algorithms, SolnNuc™ enables target identification and intelligent sequence design for small nucleic acid therapeutics including siRNA and ASO. Powered by a physics engine and RNA language foundation models, the platform precisely predicts silencing efficacy and off-target risks, enabling highly specific optimization—drastically compressing the candidate space and significantly enhancing development efficiency.
-
Target Discovery
AI algorithms rapidly screen for potential targets amenable to small nucleic acid intervention, expanding the druggable space. -
Sequence Refinement
RNA language models combined with thermodynamic mechanisms lock in the top 0.1% of high-activity sequences from a vast sequence landscape. -
Off-Target Avoidance
Automatically shields seed-region off-target risks and immunogenicity hotspots, embedding upfront safety design . -
Delivery Assessment
Provides comprehensive delivery solutions including GalNAc and LNP across diverse tissues and organs, such as liver and CNS. -
Dry-Wet Closed Loop
Active learning drives a dry-wet closed loop, reducing blind experimental rounds by over 50%, with daily iterative model updates -
Patent Circumvention
AI-generated de novo sequences effectively circumvent existing patent barriers.